Primary prevention of cardiovascular disease with statins: Assessing the evidence base behind clinical guidance

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Statins and other cholesterol-lowering drugs are increasingly being used for primary prevention of atherosclerotic cardiovascular disease. Three lines of evidence inform the development of therapeutic goals for both drug and lifestyle intervention. This evidence reveals the following principles for cholesterol lowering in primary prevention: (a) 'the more (lowering), the better' for relative risk reduction, (b) 'the lower, the better' for absolute risk reduction, and (c) 'the earlier, the better' for lifetime risk reduction. From these general axioms, treatment can be adjusted to guide therapies in individual patients. There is no 'one size fits all' for primary prevention and simplicity is not the final word for the management of cholesterol disorders; it is useful but cannot be substituted for clinical judgement.

Original languageEnglish (US)
JournalClinical Pharmacist
Volume8
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Primary Prevention
Cardiovascular Diseases
Cholesterol
Risk Reduction Behavior
Numbers Needed To Treat
Pharmaceutical Preparations
Life Style
Therapeutics

Keywords

  • Cholesterol
  • Epidemiology
  • Ezetimibe
  • Genetic epidemiology
  • Ldl
  • Lifestyle intervention
  • Primary prevention
  • Statin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacy

Cite this

@article{b1131840a06b4408a717d3451c2b6f2c,
title = "Primary prevention of cardiovascular disease with statins: Assessing the evidence base behind clinical guidance",
abstract = "Statins and other cholesterol-lowering drugs are increasingly being used for primary prevention of atherosclerotic cardiovascular disease. Three lines of evidence inform the development of therapeutic goals for both drug and lifestyle intervention. This evidence reveals the following principles for cholesterol lowering in primary prevention: (a) 'the more (lowering), the better' for relative risk reduction, (b) 'the lower, the better' for absolute risk reduction, and (c) 'the earlier, the better' for lifetime risk reduction. From these general axioms, treatment can be adjusted to guide therapies in individual patients. There is no 'one size fits all' for primary prevention and simplicity is not the final word for the management of cholesterol disorders; it is useful but cannot be substituted for clinical judgement.",
keywords = "Cholesterol, Epidemiology, Ezetimibe, Genetic epidemiology, Ldl, Lifestyle intervention, Primary prevention, Statin",
author = "Grundy, {Scott M}",
year = "2016",
month = "2",
day = "1",
doi = "10.1211/CP.2016.20200568",
language = "English (US)",
volume = "8",
journal = "Clinical Pharmacist",
issn = "1758-9061",
publisher = "Pharmaceutical Press",
number = "2",

}

TY - JOUR

T1 - Primary prevention of cardiovascular disease with statins

T2 - Assessing the evidence base behind clinical guidance

AU - Grundy, Scott M

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Statins and other cholesterol-lowering drugs are increasingly being used for primary prevention of atherosclerotic cardiovascular disease. Three lines of evidence inform the development of therapeutic goals for both drug and lifestyle intervention. This evidence reveals the following principles for cholesterol lowering in primary prevention: (a) 'the more (lowering), the better' for relative risk reduction, (b) 'the lower, the better' for absolute risk reduction, and (c) 'the earlier, the better' for lifetime risk reduction. From these general axioms, treatment can be adjusted to guide therapies in individual patients. There is no 'one size fits all' for primary prevention and simplicity is not the final word for the management of cholesterol disorders; it is useful but cannot be substituted for clinical judgement.

AB - Statins and other cholesterol-lowering drugs are increasingly being used for primary prevention of atherosclerotic cardiovascular disease. Three lines of evidence inform the development of therapeutic goals for both drug and lifestyle intervention. This evidence reveals the following principles for cholesterol lowering in primary prevention: (a) 'the more (lowering), the better' for relative risk reduction, (b) 'the lower, the better' for absolute risk reduction, and (c) 'the earlier, the better' for lifetime risk reduction. From these general axioms, treatment can be adjusted to guide therapies in individual patients. There is no 'one size fits all' for primary prevention and simplicity is not the final word for the management of cholesterol disorders; it is useful but cannot be substituted for clinical judgement.

KW - Cholesterol

KW - Epidemiology

KW - Ezetimibe

KW - Genetic epidemiology

KW - Ldl

KW - Lifestyle intervention

KW - Primary prevention

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=84959257937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959257937&partnerID=8YFLogxK

U2 - 10.1211/CP.2016.20200568

DO - 10.1211/CP.2016.20200568

M3 - Article

AN - SCOPUS:84959257937

VL - 8

JO - Clinical Pharmacist

JF - Clinical Pharmacist

SN - 1758-9061

IS - 2

ER -